Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408170 | 0.88 | KDR (0.58) | AURKAKDRAURKBMEN1KMT2A | |
| SCHEMBL1408502 | 0.86 | AURKA (0.55) | AURKAKDRAURKBMEN1KMT2A | |
| SCHEMBL2200833 | 0.83 | AURKA (0.52) | AURKAKDRAURKBLMNASMN1; SMN2 | |
| SCHEMBL2202017 | 0.82 | NR2E1 (0.77) | NR2E1 | |
| SCHEMBL2202607 | 0.81 | AURKA (0.50) | AURKAKDRAURKBLMNASMN1; SMN2 | |
| SCHEMBL2202246 | 0.81 | AURKA (0.49) | AURKAKDRAURKBMEN1KMT2A | |
| SCHEMBL2205887 | 0.80 | AURKA (0.51) | AURKAKDRAURKBLMNASMN1; SMN2 | |
| SCHEMBL3035199 | 0.80 | SMN1; SMN2 (0.67) | AURKAKDRAURKBMAPTLMNA | |
| SCHEMBL2203765 | 0.79 | MKNK2 (0.52) | AURKAKDRAURKBLMNARET | |
| SCHEMBL1408423 | 0.79 | AURKA (0.50) | AURKAKDRAURKBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | AURKA 198/4885KDR 1923/4885AURKB 287/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | AURKA 189/4885KDR 1839/4885AURKB 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.